Propofol Inhibits Invasion and Growth of Ovarian Cancer Cells Via Regulating MiR-9/NF-κB Signal
Overview
General Medicine
Affiliations
Propofol is one of the most commonly used intravenous anesthetic agents during cancer resection surgery. A previous study has found that propofol can inhibit invasion and induce apoptosis of ovarian cancer cells. However, the underlying mechanisms are not known. miR-9 has been reported to be little expressed in ovarian cancer cells, which has been related to a poor prognosis in patients with ovarian cancer. Studies have also demonstrated that propofol could induce microRNAs expression and suppress NF-κB activation in some situations. In the present study, we assessed whether propofol inhibits invasion and induces apoptosis of ovarian cancer cells by miR-9/NF-κB signaling. Ovarian cancer ES-2 cells were transfected with anti-miR-9 or p65 cDNA or p65 siRNA for 24 h, after which the cells were treated with different concentrations of propofol (1, 5, and 10 μg/mL) for 24 h. Cell growth and apoptosis were detected using MTT assay and flow cytometry analysis. Cell migration and invasion were detected using Transwell and Wound-healing assay. Western blot and electrophoretic mobility shift assay were used to detect different protein expression and NF-κB activity. Propofol inhibited cell growth and invasion, and induced cell apoptosis in a dose-dependent manner, which was accompanied by miR-9 activation and NF-κB inactivation. Knockdown of miR-9 abrogated propofol-induced NF-κB activation and MMP-9 expression, reversed propofol-induced cell death and invasion of ES-2 cells. Knockdown of p65 inhibited NF-κB activation rescued the miR-9-induced down-regulation of MMP-9. In addition, overexpression of p65 by p65 cDNA transfection increased propofol-induced NF-κB activation and reversed propofol-induced down-regulation of MMP-9. Propofol upregulates miR-9 expression and inhibits NF-κB activation and its downstream MMP-9 expression, leading to the inhibition of cell growth and invasion of ES-2 cells.
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells.
Sue S, Tseng W, Wu Z, Huang S, Chen J, Wu Z J Ovarian Res. 2024; 17(1):187.
PMID: 39272193 PMC: 11401282. DOI: 10.1186/s13048-024-01509-x.
Yao L, Zhai W, Jiang Z, He R, Xie W, Li Y Anticancer Agents Med Chem. 2024; 24(11):878-888.
PMID: 38571352 DOI: 10.2174/0118715206283884240326170501.
Does the Choice of Anaesthesia Affect Cancer? A Molecular Crosstalk between Theory and Practice.
Debel W, Ramadhan A, Vanpeteghem C, Forsyth R Cancers (Basel). 2023; 15(1).
PMID: 36612205 PMC: 9818147. DOI: 10.3390/cancers15010209.
Bonvini J Medicina (Kaunas). 2022; 58(9).
PMID: 36143832 PMC: 9503073. DOI: 10.3390/medicina58091156.
Zhu X, Peng C, Peng Z, Chang R, Guo Q Cell Transplant. 2022; 31:9636897221104447.
PMID: 35699095 PMC: 9201366. DOI: 10.1177/09636897221104447.